Navigation Links
US cancer deaths down but far too few Americans screened for colon cancer
Date:2/19/2008

BETHESDA, MD, February 20, 2008 New data revealing decreasing trends in cancer deaths in the United States overall, and in colorectal cancer deaths in particular, highlight the remarkable benefits of colorectal cancer screening tests, but the lifesaving potential of these tests is unrealized for many Americans according to experts from the American College of Gastroenterology. Racial minorities, uninsured Americans and even Medicare patients who should be tested are not being screening appropriately, and other recent studies reveal that they are diagnosed with more advanced cancers compared to patients with private insurance.

Today, the American Cancer Society reported a downward trend in cancer deaths between 2004 and 2005. Deaths from cancer of the colon and rectum decreased from 1998 to 2004 among both men and women, according to ACS. The report attributes early detection to this sharp decline in colon cancer deaths. Early detection of colorectal cancer, when it is most treatable, directly results in improved survival, exceeding 90 percent when detected at the earliest stage.

According to ACG President Amy E. Foxx-Orenstein, D.O., FACG, The good news is that colorectal cancer deaths are down, but marked differences in the experience of colorectal cancer, its impact on quality of life, and death rates are seen between whites and blacks, and between the uninsured, and even those with health coverage under Medicare and Medicaid. According to Dr. Foxx-Orenstein, The American College of Gastroenterology is committed to national policy changes to improve access to colorectal screening and increased use of these proven prevention strategies, including reversing Medicares massive cuts to reimbursement for these tests since the benefit was first introduced, as well as to payments in ambulatory surgery centers where many screening tests are performed.

Recent Studies Reveal Underuse of Colorectal Screenings, Late Stage Cancer Diagnoses

An analysis published in ACS journal CANCER in January 2008 of over 150,000 Medicare beneficiaries revealed that only 25 percent received recommended screenings for colorectal cancer since Medicare started to cover preventive screening tests. This finding reflects a significant underuse of proven screening tests among Medicare patients, and echoes other recent findings that Medicaid patients and the uninsured generally are being diagnosed with colorectal cancer at later stages, when the prognosis is far worse.

A study by Halpern et al. published in The Lancet Oncology on February 18, 2008 found a correlation between insurance status and stage of cancer diagnosis. According to the Halpern analysis, uninsured patients were two to three times more likely to be diagnosed at late stages (Stage III or State IV) than at Stage I. The disparity was most pronounced among cancers that could be detected early through screening or symptom assessment including colorectal cancer. The analysis also looked at racial background and found late state diagnosis for ten of twelve cancers among African Americans compared to whites.

ACG Recommends Earlier Screening for African-Americans: Begin at Age 45

African-Americans are diagnosed with colorectal cancer at a younger age than other ethnic groups, and African-Americans with colorectal cancer have decreased survival compared with other ethnic groups. Physician experts from the American College of Gastroenterology in 2005 issued new recommendations to healthcare providers to begin colorectal cancer screening in African-Americans at age 45 rather than 50. Colonoscopy is the preferred method of screening for colorectal cancer and data support the recommendation that African-Americans begin screening at a younger age because of the high incidence of colorectal cancer and a greater prevalence of proximal or right-sided polyps and cancerous lesions in this population. The recommendations were published in the March 2005 issue of The American Journal of Gastroenterology.

Colorectal Cancer ScreeningRecommendations from the American College of Gastroenterology

For normal risk individuals, the American College of Gastroenterology recommends screening beginning at age 50 (age 45 for African-Americans). The preferred screening test according to the American College of Gastroenterology is colonoscopy every 10 years. An alternative strategy for average risk individuals is an annual stool test for blood, and a flexible sigmoidoscopic exam every 5 years. Unlike colonoscopy, this approach does not allow identification and removal of polyps in the entire colon.

For those with a family history of colorectal cancer, testing should begin at 40 years of age or 10 years younger than the age of the youngest affected relative at the time of colon cancer diagnosis, whichever is earlier. For both average and high risk individuals, all potential precancerous polyps should be removed.


'/>"/>

Contact: Rosanne Riesenman
mediaonly@acg.gi.org
301-263-9000
American College of Gastroenterology
Source:Eurekalert

Related medicine news :

1. U.S. Cancer Deaths Down But Far Too Few Americans Screened for Colon Cancer
2. Gene therapy trains immune system to destroy brain cancer cells and reverses behavioral deficits
3. NIST, NCI, SAIC partner on new method for detecting HER2 breast cancer
4. Combo Treatment Best for Melanoma, Advanced Ovarian Cancer
5. Overweight and obese men have lower PSA values, even before they get prostate cancer
6. Charles Lafitte Foundation Pledges $1 Million to the American Cancer Societys Hope Lodge
7. Vaccine/antibody therapy effective, milder side effects in melanoma and ovarian cancer
8. Optimal band imaging with endoscopy facilitates the diagnosis of depressed-type early gastric cancer
9. Timely Cancer Diagnosis Linked to Insurance Status
10. UNT Health Science Center and The Center for Cancer and Blood Disorders Collaborate on New Institute for Cancer and Blood Disorders
11. Major study links insurance status to advanced stage in multiple cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... December 07, 2016 , ... Gensuite ... Brilliance Awards under the Best New Product Launch category. Gensuite’s entry on their ... experience. , BOC Global Events & Training Group is a professional event and ...
(Date:12/7/2016)... ... December 07, 2016 , ... “The Road To Restoration”: an ... not a one hour a week showing of hands. “The Road To Restoration” is ... “Perhaps you are familiar with the brass ring that you could reach out for, ...
(Date:12/7/2016)... , ... December 07, 2016 , ... “Fred Rides a ... Christmas Day that follows. , “Fred Rides a Train” is the creation of ... short stories since her teen years in Michigan. The "Fred, the Dog" series is ...
(Date:12/7/2016)... ... 2016 , ... Dr. Greg Leyer, the Chief Scientific Officer ... DC workshop on November 2nd. The conference was an opportunity for both probiotic ... regulations. , Dr. Leyer spoke about two main topics at the IPA ...
(Date:12/6/2016)... ... 06, 2016 , ... People with Parkinson’s disease and cognitive ... type of MRI, according to a study appearing online in the journal Radiology. ... characterized by tremors or trembling and stiffness in the limbs, impaired balance and ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)... Dec. 6, 2016 Eurofins Genomics today ... the College of American Pathologists (CAP) and certification ... its new laboratory in Louisville, KY ... North American headquarters. "Our new CLIA-licensed ... which is still considered the ,Gold Standard, method ...
(Date:12/6/2016)... WESTLAKE VILLAGE, Calif. , Dec. 6, ... a privately held, clinical-stage medical dermatology and ... Creabilis plc, a privately held specialty pharmaceutical ... for common inflammatory skin conditions, including psoriasis, ... terms of the agreement, Sienna will make ...
(Date:12/6/2016)... 2016  Regulus Therapeutics Inc. (NASDAQ: ... and development of innovative medicines targeting microRNAs, today ... R&D day, held in New York ... anti-miR targeting microRNA-27 (miR-27) for the treatment of ... anti-miR targeting microRNA-17 (miR-17) for the treatment of ...
Breaking Medicine Technology: